The Neuroprotective Effect of Pioglitazone on NB2a Mouse Neuroblastoma Cell Culture

Pioglitazone (PGT) is a PPAR-γ activator that has neuroprotective properties via different mechanisms. It is thought to be neuroprotective in both acute and chronic use. Chlorpyrifos (CPS) is an Organophosphate insecticide that leads to attention deficit and cognitive problems in children and its neurotoxic effects are well known. This study aims to investigate the neuroprotective effects of PGT on CPS neurotoxicity in NB2a cell in the culture medium. We investigated the cell viability and proliferation using MTT assay and the percentage of neurite inhibition was analysed by measuring neurite outgrowth. Apoptosis was evaluated using the apoptotic index in TUNEL staining. Cell proliferation was found to be significantly reduced by CPS (25 μM), and this concentration-based reduction was prevented by PGT. Neurite outgrowth was inhibited by CPS (25 μM), whereas PGT significantly reversed neurite inhibition at and above 10 μM concentrations. The apoptotic index, which was increased using CPS (25 μM), was observed to reduce using PGT, depending on the concentration. Organophosphate is harmful to human health, and to our knowledge, there is no treatment. In individuals exposed to chlorpyrifos toxicity, acute toxic effects on neurons may be prevented or treated by PGT.

Pioglitazonun NB2a Fare Nöroblastoma Hücre Kültürüdeki Nöroprotektif Etkisi

Pioglitazon (PGT), farklı mekanizmalar yoluyla nöroprotektif özelliklere sahip bir PPAR-γ aktivatörüdür. PGT akut ve kronik kullanımının nöroprotektif olduğu düşünülmektedir. Klorpirifos (CPS) çocuklarda dikkat eksikliği ve bilişsel problemlere yol açan bir organofosfat insektisit olup nörotoksik etkileri iyi bilinmektedir. Bu çalışmada, kültür ortamında fare kaynaklı NB2a kanser dizin hücrelerinde CPS nörotoksisitesi üzerine PGT’nin nöroprotektif etkileri olup olmadığının araştırdık. MTT analizini kullanarak hücre proliferasyonu üzerine etkilerini ve ılımlı nörotoksik etkinin bir göstergesi olan Nörotoksisite Tarama Testi ile % nörit inhibisyonu incelendi. Apopitoz, TUNEL boyamada apopitotik indeks kullanılarak değerlendirildi. CPS (25 μM) konsantrasyonda uygulandığında NB2a hücre proliferasyonu azalttı. PGT ise konsantrasyon bağlı olarak klorpirosa bağlı azalmayı önlendi. Klorpirifon 25 μM konsantrasyonda tama yakın Nörit uzamasını inhibe ederken, PGT 10 μM ve üzerindeki konsantrasyonlarda nörit inhibisyonunu önemli ölçüde engelledi. CFS (25 μM) ile artan apopitotik hücre sayısını, PGT 10 uM konsantarasyondan itibaren anlamlı düzeyde azalttığı görüldü. Organofosfatlar insan sağlığına zararlıdır ve toksik etkilerini önlemek için bildiğimiz bir tedavisi yoktur. Klorpirifos toksisitesine maruz kalan bireylerde, nöronlar üzerindeki akut toksik etkileri PGT ile önlenebilir veya tedavi edilebilir.

PDF

___

1. Brody H: The nervous system and aging. Adv Pathobiol, 7, 200-209, 1980.

2. Sindi RA, Harris W, Arnott G, Flaskos J, Mills LC, Hargreaves AJ: Chlorpyrifos- and chlorpyrifosoxon-induced neurite retraction in predifferentiated N2a cells is associated with transient hyperphosphorylation of neurofilament heavy chain and ERK 1/2. Toxicol Appl Pharmacol, 308, 20-31, 2016. DOI: 10.1016/j.taap.2016.08.008

3. Swanson CR, Du E, Johnson DA, Johnson JA, Emborg ME: Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-γ agonist against MPTP. PPAR Res, 2013:582809, 2013. DOI: 10.1155/2013/582809

4. Cippitelli A, Domi E, Ubaldi M, Douglas JC, Li HW, Demopulos G, Gaitanaris G, Roberto M, Drew PD, Kane CJM, Ciccocioppo R: Rotection against alcohol-induced neuronal and cognitive damage by the PPARγ receptor agonist pioglitazone. Brain Behav Immun, 64, 320-329, 2017. DOI: 10.1016/j.bbi.2017.02.001

5. Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, da Cunha C, Vital MA: Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6- tetrahyropyridine. Behav Brain Res, 274, 390-399, 2014. DOI: 10.1016/j. bbr.2014.08.014

6. Slørdal L, Spigset O: Heart failure induced by non-cardiac drugs. Drug Saf, 29, 567-586, 2006. DOI: 10.2165/00002018-200629070-00003

7. Elshama S, El-Kenawy A, Osman HE: Toxicological evaluation of subchronic use of pioglitazone in mice. Iran J Basic Med Sci, 19, 712-719, 2016. DOI: 10.22038/IJBMS.2016.7353

8. Lau K, McLean WG, Williams DP, Howard CV: Synergistic interactions between commonly used food additives in a developmental neurotoxicity test. Toxicol Sci, 90, 178-187, 2006. DOI: 10.1093/toxsci/kfj073

9. McLean WG. Holme AD, Janneh O, Southgate A, Howard CV, Reed MG: The effect of benomyl on neurite outgrowth in mouse NB2A and human SH-SY5Y neuroblastoma cells in vitro. Neurotoxicology, 19, 629- 632, 1998.

10. Bilir EK, Tutun H, Sevin S, Kismali G, Yarsan E: Cytotoxic effects of Rhododendron ponticum L. extract on prostate carcinoma and adenocarcinoma cell line (DU145, PC3). Kafkas Univ Vet Fak Derg, 24 (3): 451-457, 2018. DOI: 10.9775/kvfd.2017.19219

11. Vural K, Tuglu MI: Neurotoxic effect of statins on mouseneuroblastoma NB2a cellline. Eur Rev Med Pharmacol Sci, 15, 985-991, 2011.

12. Mete M, Aydemir I, Unlu Unsal U, Duransoy YK, Tuglu MI, Selçuki M: Neuroprotective effects of bone marrow-derived mesenchymal stem cells and conditioned medium in mechanically injured neuroblastoma cells. Turk J Med Sci, 20, 1900-1907, 2016. DOI: 10.3906/sag-1507-187

13. Sachana M, Flaskos J, Nikolaidis E, Hargreaves A, Alexaki- Tzivanidou E: Inhibition of rat platelet 5-hydroxytryptamine uptake by chlorpyrifos and carbaryl. Pharmacol Toxicol, 89, 195-200, 2001. DOI: 10.1111/j.0901-9928.2001.890409.x

14. Schuh RA, Lein PJ, Beckles RA, Jett DA: Noncholinesterase mechanisms of chlorpyrifos neurotoxicity: Altered phosphorylation of Ca2+/cAMP response element binding protein in cultured neurons. Toxicol Appl Pharmacol, 15, 176-185, 2002. DOI: 10.1006/taap.2002.9445

15. Axelrad JC, Howard CV, McLean WG: The effects of acute pesticide exposure on neuroblastoma cells chronically exposed to diazinon. Toxicology, 185, 67-78, 2003. DOI: 10.1016/S0300-483X(02)00592-9

16. Barbiero JK, Santiago RM, Lima MMS, Ariza D, Morais LH, Andreatini R, Vital MABF: Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson’s disease. Behav Brain Res, 216, 186-192, 2011. DOI: 10.1016/j.bbr.2010.07.033

17. Harry GJ, Billingsley M, Bruinink A, Campbell IL, Classen W, Dorman DC, Gali C, Ray D, Smith RA, Tilson HA: In vitro echniques for the assessment of neurotoxicity. Environ Health Perspect, 106, 131-158, 1998. DOI: 10.1289/ehp.98106s1131

18. Veronesi B, Ehrich M: Differential cytotoxic sensitivity in mouse and human cell lines exposed to organophosphate insecticides. Toxicol Appl Pharmacol, 12, 240-246, 1993. DOI: 10.1006/taap.1993.1108

19. Bottenstein JE, Sato G: Cell Culture and the Neurosciences. New York: Plenum Press, 1985.

20. Ehrich M, Correll L, Veronesi B: Neuropathy target esterase inhibition by organophos-phorus esters in human neuroblastoma cells. Neurotoxicology, 15, 309-313, 1994.

21. Drew PD, Johnson JW, Douglas JC, Phelan KD, Kane CJ: Pioglitazone blocks ethanol induction of microglial activation and immune responses in the hippocampus, cerebellum, and cerebral cortex in a mouse model of fetal alcohol spectrum disorders. Alcohol Clin Exp Res, 39, 445-454, 2015. DOI: 10.1111/acer.12639

22. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ: The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamineoxidase B. Br J Pharmacol, 154, 226-233, 2008. DOI: 10.1038/bjp.2008.78

23. Krishnan A, Nair SA, Pillai MR: Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med, 7, 532-540, 2007. DOI: 10.2174/156652407781695765

24. Kim KY, Kim SS, Cheon HG: Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol, 72, 530-540, 2006. DOI: 10.1016/j. bcp.2006.05.009

25. Plutzky J: Medicine. PPARs as therapeutic targets: Reverse cardiology? Science, 17, 406-407, 2003. DOI: 10.1126/science.1091172

26. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R: Oxidative stress and inflammatory response evoked by transient cerebral ischemia/ reperfusion: Effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med, 41, 579-589, 2006. DOI: 10.1016/j.freeradbiomed.2006.04.030

27. Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J: Peroxisomeproliferator- activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res, 1073-1074, 460-496, 2006. DOI: 10.1016/j.brainres.2005.12.061

28. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira- Garcia JL: Involvement of PPAR-γ in the neuroprotective and antiinflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease. J Neuroinflammation, 9:38, 2012. DOI: 10.1186/1742-2094-9-38

29. Pang T, Sun LX, Wang T, Jiang ZZ, Liao H, Zhang LY: Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway. Acta Pharmacol Sin, 35, 727-737, 2014. DOI: 10.1038/aps.2013.199

30. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A: The PPAR-γ agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation, 9, 63, 2012. DOI: 10.1186/1742-2094-9-63

31. Kumar P, Kaundal RK, More S, Sharma SS: Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav Brain Res, 197, 398-403, 2009. DOI: 10.1016/j.bbr.2008.10.010

32. Lee JE, Park JH, Jang SJ, Koh HC: Rosiglitazone inhibits chlorpyrifosinduced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells. Toxicol Appl Pharmacol, 278, 159- 171, 2014. DOI: 10.1016/j.taap.2014.04.021

33. Moon HS, Dincer F, Mantzoros CS: Amylin-induced down regulation of hippocampal neurogenesis is attenuated by leptin in a STAT3/AMPK/ ERK-dependent manner in mice. Diabetologia, 56, 627-634, 2013. DOI: 10.1007/s00125-012-2799-3

34. Vingtdeux V, Davies P, Dickson DW, Marambaud P: AMPK is abnormallyactivated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies. Acta Neuropathol, 121, 337- 349, 2011. DOI: 10.1007/s00401-010-0759-x

35. Cai Z, Li B, Li K, Zhao B: Down-regulation of amyloid-β through AMPK activation by inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 cells. J Alzheimers Dis, 29, 89-98, 2012.DOI: 10.3233/JAD-2012-111649

36. Dief AE, Kamha ES, Baraka AM, Elshorbagy AK: Monosodium glutamate neurotoxicity increases beta amyloid in the rat hippocampus: A potential role forcyclic AMP protein kinase. Neurotoxicology, 42, 76-82, 2014. DOI: 10.1016/j.neuro.2014.04.003

37. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL: Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta, 301, 65-77, 2000. DOI: 10.1016/S0009- 8981(00)00327-2

38. Niture NT, Ansari AA, Naik SR: Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: An effect mediated through cytokines, antioxidants and lipid biomarkers. Indian J Exp Biol, 52, 720- 727, 2014.

39. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O: Distinct modulation of voltage-gated and ligandgated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem, 109, 1800-1811. 2009. DOI: 10.1111/j.1471- 4159.2009.06107.x

40. Xue YJ, Turner KC, Meeker JB, Pursley J, Arnold M, Unger S: Quantitative determination of pioglitazone in human serum by directinjection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci, 795, 215-226, 2003.